Lillian Smith - 01 Apr 2023 Form 4 Insider Report for Allogene Therapeutics, Inc. (ALLO)

Reporting relationship: VP, Corporate Counsel
Issuer ticker: ALLO
Reported as of: 01 Apr 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Apr 2023, 18:43:25 UTC
Source filing: View source filing
Reporting owner signature: /s/Lillian Smith

Key filing fact

Lillian Smith filed Form 4 for Allogene Therapeutics, Inc. (ALLO) on 05 Apr 2023.

Key facts

This page summarizes Lillian Smith's Form 4 filing for Allogene Therapeutics, Inc. (ALLO).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 05 Apr 2023, 18:43.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ALLO transaction

Common Stock

Award

Transaction value: $0
Shares: +56,545
Change %: +67%
Price: $0.000000
Shares after: 140,390
Date: 01 Apr 2023
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents performance RSUs which shall vest as follows: (1) 33% shall vest if the 30-day weighted average stock price is equal to or greater than $18 and (2) 67% shall vest upon the first regulatory approval of a product candidate. Notwithstanding the foregoing (1) any portion that vests upon the stock price threshold shall no longer vest and be terminated on March 22nd, 2026 if such threshold has not been met, and (2) any portion that vests upon product candidate approval shall no longer vest and be terminated after March 22nd, 2028 if such approval has not occurred.